Drugs in Tuberculosis and Leprosy

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

The treatment of tuberculosis and leprosy requires the utilization of combination regimens commonly including agents with variable toxicity profiles that may be further exacerbated by drug–drug interactions and patient-specific factors. The increase in incorporation of older and novel agents to treatment regimens has revealed unique adverse effect profiles and added to the previous understanding of these drug's adverse effect profiles. In this chapter we review the pertinent literature from 2017 regarding adverse effects for the following agents: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, delamanid, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thioacetazone.

Original languageEnglish
Title of host publicationSide Effects of Drugs Annual
EditorsSidhartha D. Ray
PublisherElsevier B.V.
Pages363-376
Number of pages14
ISBN (Print)9780444641199
DOIs
StatePublished - 1 Jan 2018

Publication series

NameSide Effects of Drugs Annual
Volume40
ISSN (Print)0378-6080

    Fingerprint

Keywords

  • Adverse effects
  • Ethambutol
  • Isoniazid
  • Leprosy
  • Pyrazinamide
  • Rifamycins
  • Side effect
  • Tuberculosis

Cite this

Ramanathan, M. R., Howell, C. K., & Sanders, J. M. (2018). Drugs in Tuberculosis and Leprosy. In S. D. Ray (Ed.), Side Effects of Drugs Annual (pp. 363-376). (Side Effects of Drugs Annual; Vol. 40). Elsevier B.V.. https://doi.org/10.1016/bs.seda.2018.06.014